Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2005
12/13/2005US6974684 Introducing a sample containing specific polypeptide to an antibody that binds immunospecifically to the polypeptide and determining the presence or amount of antibody bound to such polypeptide
12/13/2005US6974683 Polypeptide for use in the diagnosis and treatment of cancer
12/13/2005US6974594 Method of preparing biological materials and preparations produced using same
12/13/2005US6974593 Spraying a compressed fluid comprising a water insoluble active material in solvent, into an aqueous solution comprising a surfactant, forming microparticles; increase the drug bioavailability
12/13/2005US6974585 Film-forming cyanoacrylate with mixture of antibiotics for forming antibiotic containing film in situ over mammalian tissue
12/13/2005US6974579 improving blood supply through a grafted blood vessel by administering a botulinum toxin to the grafted blood vessel
12/13/2005US6974578 for relieving pain associated with muscle contractions and cholinergic controlled secretions including excessive sweating
12/13/2005US6974571 Isolated stromal cells and methods of using the same
12/13/2005US6974247 Device for mixing and/or injecting cements
12/13/2005CA2403947C Bir domains of mammalian iap gene family
12/13/2005CA2324403C Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
12/13/2005CA2256596C Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
12/13/2005CA2090634C Novel cyclosporins
12/11/2005CA2467769A1 Methods and formulations for testosterone suppression
12/09/2005WO2005123108A2 Advanced vitamins and protein based nutritional supplements
12/09/2005CA2514687A1 Advenced vitamin c-based composition with enhanced biotransformation and utilization of protein and l-carnitine for nutritional supplementation or the like
12/08/2005WO2005116657A2 Identification of ergothioneine transporter and therapeutic uses thereof
12/08/2005WO2005116655A2 Natriuretic compounds, conjugates, and uses thereof
12/08/2005WO2005116649A1 Method of screening vascular smooth muscle cell growth inhibitor and growth promoter
12/08/2005WO2005116247A1 Method and device for the in vitro detection of polycystic ovarian syndrome (pcos) and pathologies involving cardiovascular risk
12/08/2005WO2005116235A2 Endothelial cell apoptosis induced by fibrinogen gamma chain c-terminal fragment
12/08/2005WO2005116225A1 Method for introducing and expressing rna in cells
12/08/2005WO2005116218A1 Fusion gene of hepatitis b surface antigen with carboxyl end having pres2 immune determinant and the protein thereof
12/08/2005WO2005116201A1 TYROSINE KINASE TNK FOR USE AS INHIBITOR FOR NUCLEAR TRANSCRIPTION FACTOR KAPPA B (NFκB)
12/08/2005WO2005116197A2 Adamts-8 proteins and uses thereof
12/08/2005WO2005116075A1 High affinity telomerase t cell receptors
12/08/2005WO2005116068A1 Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities
12/08/2005WO2005116067A2 Msh-agonist tripeptide conjugates
12/08/2005WO2005116066A1 Peptides derived from decorin leucine rich repeats and uses thereof
12/08/2005WO2005116062A1 Products and uses thereof
12/08/2005WO2005116060A1 Polypeptide increasing the monoclonal antibody production, nucleic acid encoding same and use thereof
12/08/2005WO2005116058A1 Peptides useful for treating gnrh associated diseases
12/08/2005WO2005116055A1 Peptides, antibodies and compositions containing same useful for treating hiv virus infection
12/08/2005WO2005116053A1 Novel hair growth stimulant
12/08/2005WO2005116051A2 Tumor-associated peptides that bind to mhc-molecules
12/08/2005WO2005115547A2 Myricitrin compounds for sleeping disorders
12/08/2005WO2005115517A2 Methods of treating diabetes
12/08/2005WO2005115480A2 Modified protein kinase a-specific oligonucleotides and methods of their use
12/08/2005WO2005115476A1 Drug comprising as the active ingredient proliferative vector containing survivin promoter
12/08/2005WO2005115460A1 A method of producing polypeptides from plant protein and use of polypeptides
12/08/2005WO2005115455A2 Methods and reagents for the treatment of immunoinflammatory disorders
12/08/2005WO2005115446A2 Detection and use of prolylcarboxypeptidase
12/08/2005WO2005115445A1 Enzymes for pharmaceutical use
12/08/2005WO2005115444A2 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
12/08/2005WO2005115443A1 Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone
12/08/2005WO2005115442A1 Use of coagulation factor xiii for treatment of post surgical bleedings
12/08/2005WO2005115441A2 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
12/08/2005WO2005115440A2 Compositions and method for modulating insulin-activated nitric oxide synthase
12/08/2005WO2005115439A2 Cerberus/coco derivatives and uses thereof
12/08/2005WO2005115438A1 Use of morphogenic proteins for treating cartilage defects
12/08/2005WO2005115437A2 Methods for affecting body composition
12/08/2005WO2005115436A1 Soluble lfa-3 polypeptide for treating viral disorders
12/08/2005WO2005115435A2 Methods and compositions for control of fetal growth via modulation of relaxin
12/08/2005WO2005115434A1 Therapeutic compositions and methods for treating hpv induced skin cancer
12/08/2005WO2005115433A2 Methods for cyclizing synthetic polymers
12/08/2005WO2005115432A2 Treatment of ocular diseases and disorders using lantibiotic compositions
12/08/2005WO2005115431A2 Methods for inhibiting proteasome and heat shock protein 90
12/08/2005WO2005115430A1 Treatment of inflammatory airway disease
12/08/2005WO2005115429A1 Methods and kits for diagnosing and/or assessing severity and treating gaucher disease
12/08/2005WO2005115405A1 Methods for treating or preventing restenosis and other vascular proliferative disorders
12/08/2005WO2005115394A2 Prenyl-electrostatic switch, and methods of use
12/08/2005WO2005115371A1 Pharmaceutical compositions for the prevention and treatment of atherosclerosis
12/08/2005WO2005115367A2 Modulation of neurotransmitter activity in neurons
12/08/2005WO2005115337A1 Superloaded liposomes for drug delivery
12/08/2005WO2005115333A2 A biomolecule-containing formulation of increased stability
12/08/2005WO2005115174A2 Alpha-msh-antagonist didpeptide conjugates
12/08/2005WO2005115173A1 Medicinal products incorporating bound organosulfur groups
12/08/2005WO2005115149A2 Insectidal activity of a cyclic peptide
12/08/2005WO2005115136A2 Transgenic models of alzheimer’s disease and uses thereof in the treatment of a variety of neurodegenerative diseases
12/08/2005WO2005115097A2 Cyclic peptide antibiotics
12/08/2005WO2005105148A8 Liquid growth hormone formulation
12/08/2005WO2005097828A3 Peptides of cav2.2 that inhibit pain
12/08/2005WO2005093069A3 Production of mersacidin and its variants in sigh and/or mrsa negative bacillus host cells
12/08/2005WO2005092921A3 Placental growth factor splice variants and their uses
12/08/2005WO2005091956A3 In vitro test system for predicting patient tolerability of therapeutic agents
12/08/2005WO2005084695A3 Use of carboxypeptidase g for combating antifolate toxicity
12/08/2005WO2005084652A3 Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
12/08/2005WO2005082080A3 Method to modulate the immune system with a novel guanine nucleotide exchange factor
12/08/2005WO2005081649A3 Preparation for reducing protein deficiency in an organism and method for the production thereof
12/08/2005WO2005079829A3 Method for treating glaucoma
12/08/2005WO2005079827A3 Antitumor agent
12/08/2005WO2005078075A3 Hybrid proteins of active-site serine beta-lactamase
12/08/2005WO2005075436A3 Novel inhibitors of glutaminyl cyclase
12/08/2005WO2005074973A3 Method of inducing or modulating immune response
12/08/2005WO2005074968A3 Medical use of basic peptides
12/08/2005WO2005070450A3 Use of low-dose erythropoietin for the treatment of acute or chronic kidney failure and for the treatment of wounds
12/08/2005WO2005070447A3 M-csf muteins and uses thereof
12/08/2005WO2005065308A3 Compositions and methods to treat recurrent medical conditions
12/08/2005WO2005053725A3 Cancer treatment
12/08/2005WO2005051232A3 Soft tissue implants and anti-scarring agents
12/08/2005WO2005045035A3 RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/08/2005WO2005041882A3 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
12/08/2005WO2005005627A3 Applications of a new class of enzymes: sulfiredoxines.
12/08/2005WO2005000875A3 Compositions and methods comprising a ligand of chemerin receptor
12/08/2005WO2004069173A3 Methods for modulating an inflammatory response
12/08/2005WO2004069172A3 Multilineage-inducible cells and uses thereof
12/08/2005WO2004066704A3 Injectable hydrogel microspheres from aqueous two-phase system
12/08/2005WO2004050704A8 Therapeutic and diagnostic agents
12/08/2005WO2004039958A3 Lutzomyia longipalpis polypeptides and methods of use
12/08/2005WO2003104263A3 Cytokines and cytokine receptors with reduced immunogenicity
1 ... 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 ... 3163